Urinary Incontinence and Type 2 Diabetes: A Deeper Look at the Connection

Unlike Type 1 diabetes mellitus (T1DM), which is autoimmune in origin and typically diagnosed in younger individuals, T2DM is often associated with aging, obesity, insulin resistance, and hypertension—factors that collectively contribute to urinary tract dysfunction. In men with T2DM, bladder dysfunction (BD) manifests through various urodynamic abnormalities, including diabetic cystopathy (DC), detrusor overactivity, and bladder outlet obstruction (BOO). These complications correlate with disease duration, poor glycemic control (HbA1C >7.9%), and the presence of other chronic diabetic complications such as retinopathy, nephropathy, and autonomic neuropathy.

Prevalence and Comparison: T2DM vs T1DM

Men with Type 2 diabetes mellitus (T2DM) exhibit a significantly higher prevalence of lower urinary tract symptoms (LUTS) and urinary incontinence (UI) compared to non-diabetic individuals. Studies have reported that over 50% of men with T2DM experience moderate to severe LUTS, including nocturia and weak urinary stream, which are the most common symptoms observed in this population .

In T2DM, factors such as obesity, higher body mass index (BMI), metabolic syndrome, and insulin resistance are significant contributors to LUTS severity . These factors can lead to bladder outlet obstruction and detrusor overactivity. Conversely, T1DM is more strongly associated with neuropathic bladder dysfunction, known as diabetic cystopathy.

Age and duration of diabetes also play crucial roles in the severity of urologic symptoms. T2DM often remains undiagnosed for extended periods, leading to more severe urologic complications in older patients. In contrast, T1DM is typically diagnosed earlier in life, allowing for more timely management of potential complications.​

Risk Factors and Pathophysiology in T2DM

Type 2 diabetes mellitus (T2DM) is a complex metabolic disease influenced by a combination of genetic predisposition and modifiable lifestyle factors such as obesity, low physical activity, and unhealthy diets. Ethnic variations—particularly in Asians, Native Americans, and Black populations—underscore the interaction between genetic susceptibility and environmental triggers. Genome-wide association studies confirm T2DM’s polygenic nature, primarily affecting insulin secretion and, to a lesser extent, insulin action.

Pathophysiologically, T2DM is driven by insulin resistance and β-cell dysfunction, leading to chronic hyperglycemia. This sustained hyperglycemic state initiates oxidative stress, endothelial dysfunction, and vascular damage—factors implicated in diabetic bladder dysfunction and pelvic neuropathy. Bladder dysfunction in T2DM often begins with detrusor overactivity due to early polyuria and compensatory hypertrophy. Over time, neurogenic and myogenic changes result in hypocontractility or even areflexia.

Advanced glycation end-products (AGEs), common in T2DM, impair collagen and muscle tissue in the bladder, compromising its elasticity and contractility. Additionally, obesity and metabolic syndrome enhance sympathetic tone, contributing to bladder outlet obstruction.

Benign prostatic hyperplasia (BPH), more prevalent in T2DM, is exacerbated by hyperinsulinemia, which promotes smooth muscle proliferation and inflammation. Urinary tract infections are also more frequent in T2DM due to immune dysregulation and urinary stasis.

In contrast to T1DM, where neuropathy predominantly drives bladder dysfunction, T2DM encompasses a broader pathophysiological spectrum, including inflammatory, structural, and metabolic alterations—often complicated by comorbidities such as BPH.

Types of Urinary Incontinence

In men with type 2 diabetes, urinary incontinence (UI) often results from a combination of metabolic, neurologic, and urologic factors.

•  Urge incontinence, while more prevalent in type 1 diabetes due to autonomic neuropathy, also affects T2DM patients through detrusor overactivity linked to chronic inflammation. 
• Overflow incontinence, common in type 1 due to impaired sensation, often arises in T2DM from benign prostatic hyperplasia (BPH) and incomplete bladder emptying. 
• Mixed incontinence (urge + overflow) frequently occurs in long-standing or poorly controlled T2DM. 
• Stress incontinence is less typical in men but may appear with obesity-related pelvic floor weakening—a known T2DM comorbidity.

Impact on Quality of Life

Diabetes significantly affects patients' quality of life (QoL), with type 2 diabetes often leading to both physical and psychological deterioration. The World Health Organization (WHO) defines QoL as an individual's perception of their position in life in the context of their culture, expectations, and concerns, encompassing physical health, psychological state, independence, social relationships, and beliefs.

Numerous psychometric tools now assess these dimensions, reflecting a global shift toward patient-centered care. According to recent literature, diabetic complications and comorbidities—such as coronary artery disease, renal dysfunction, and depression—play a dominant role in diminishing HRQoL.

One often under recognized complication that greatly impairs QoL in individuals with type 2 diabetes is overactive bladder (OAB). A study found that 13.9% of surveyed patients with type 2 diabetes had OAB—6.1% with dry OAB and 7.8% with wet OAB (associated with urge incontinence). Importantly, the presence of OAB significantly reduced both the physical and mental components of HRQoL. The deterioration in QoL caused by OAB was even greater than that caused by some well-known diabetic complications such as neuropathy or retinopathy. These findings underscore the importance of recognizing and addressing bladder dysfunction in the routine management of type 2 diabetes, especially given that OAB is more prevalent among diabetics than in the general population.

This growing body of evidence suggests that to truly improve the lives of people with diabetes, healthcare providers must go beyond glycemic control and include regular screening for complications like OAB and mental health disorders. Personalized and continuity-based care, along with addressing both physical and psychological needs, appears to be the most promising path forward in preserving or enhancing QoL for individuals with type 2 diabetes.

Diagnosis and Clinical Assessment 

A thorough diagnostic approach is essential for type 2 diabetes mellitus (T2DM) patients with urinary incontinence (UI). Urodynamic studies are critical to evaluate detrusor overactivity, bladder compliance, outlet resistance, and post-void residual (PVR) volume—especially since diabetic neuropathy may be subclinical. Prostate assessment, including PSA testing, digital rectal examination (DRE), and transrectal ultrasound, is warranted due to the high risk of benign prostatic hyperplasia (BPH) in men with T2DM.

Bladder diaries can identify incontinence patterns, fluid intake habits, and the severity of leakage episodes, guiding treatment decisions.. Routine HbA1c and blood glucose monitoring is necessary, as poor glycemic control is associated with worsened bladder symptoms. Neurological assessments, particularly of sacral segments S2–S4, help identify peripheral neuropathy affecting bladder function.

Evaluation of UTIs and PVR via ultrasound or catheterization helps exclude infection or obstruction as contributing factors. A broader differential diagnosis is essential in T2DM due to overlapping symptoms from BPH, metabolic syndrome, and obesity. Given the variability of symptoms and the potential for subclinical neuropathy, comprehensive evaluation including urodynamics is indispensable

Management Strategies

Managing urinary incontinence in patients with type 2 diabetes requires a personalized, multidisciplinary approach that integrates lifestyle changes, pharmacotherapy, and advanced interventions.

Lifestyle Modifications:
Lifestyle changes are critical not only for glycemic control but also for managing urinary symptoms. Structured physical activity like walking, light chores, and aerobic exercises can enhance insulin sensitivity, improve vascular function, and reduce polyuria. Reducing sedentary time and managing stress—known to worsen glycemic control—are also vital. Dietary interventions include lowering intake of sugars, saturated fats, and processed foods, while incorporating high-fiber vegetables, lean proteins, and polyunsaturated fats. Fluid intake should be well-timed, avoiding excess fluid before bed. Caffeine, alcohol, and spicy foods should be limited. Nutritional therapy and education by a registered dietitian can significantly improve outcomes. Improving glycemic control, especially by combining pharmacologic and non-pharmacologic measures, helps alleviate diabetes-related bladder dysfunction.

Bladder-focused Strategies:
Kegel exercises and bladder training are beneficial for those with urge symptoms or early signs of detrusor overactivity. These interventions help strengthen pelvic floor muscles and enhance bladder control.

Pharmacotherapy:
Antimuscarinics (e.g., solifenacin, oxybutynin) are first-line for urge incontinence but must be used cautiously due to potential side effects. β3-agonists like mirabegron offer fewer CNS effects. In men with benign prostatic hyperplasia (BPH), alpha-blockers (tamsulosin) or 5-alpha reductase inhibitors may be effective. Given the high risk of polypharmacy in diabetics, careful monitoring is essential.

Advanced Therapies & Behavioral Support:
For refractory cases, intravesical botulinum toxin or sacral neuromodulation may be considered. Addressing mental health (e.g., depression, anxiety) is essential for adherence. Absorbent products like QuickChange Wraps improve hygiene, dignity, and quality of life.

Conclusion & Call to Action

Urinary incontinence in men with Type 2 diabetes is a multifaceted condition, often overlooked amid other diabetes-related complications. It stems from a blend of metabolic dysregulation, obesity, prostate issues, and insulin resistance—distinct from the primarily neuropathic origin seen in Type 1 diabetes. Early recognition and a tailored management approach, combining lifestyle changes, pharmacotherapy, and supportive tools, are essential for improving patient outcomes and quality of life.

For those seeking support, we invite you to purchase a 10 Count Trial Pack here or request a professional-use sample pack for healthcare institutions here.

References:

1. Danforth, K. N., Townsend, M. K., Curhan, G. C., Resnick, N. M., & Grodstein, F. (2009). Type 2 diabetes mellitus and risk of stress, urge and mixed urinary incontinence. Journal of Urology, 181(1), 193–197. https://doi.org/10.1016/j.juro.2008.09.007

2. Dimas, A. S., Lagou, V., Barker, A., Knowles, J. W., Mägi, R., Hivert, M. F., ... Prokopenko, I.; MAGIC Investigators. (2014). Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes, 63(6), 2158–2171. https://doi.org/10.2337/db13-0949

3. Gacci, M., Corona, G., Vignozzi, L., Salvi, M., Serni, S., De Nunzio, C., ... Maggi, M. (2015). Metabolic syndrome and benign prostatic enlargement: A systematic review and meta-analysis. BJU International, 115(1), 24–31. https://doi.org/10.1111/bju.12728

4. Geerlings, S. E., & Hoepelman, A. I. (1999). Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunology & Medical Microbiology, 26(3–4), 259–265. https://doi.org/10.1111/j.1574-695X.1999.tb01397.x

5. Harris, S., Leslie, S. W., & Riggs, J. (2024). Mixed Urinary Incontinence. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534234/

6. He, Q., Wu, L., Deng, C., He, J., Wen, J., Wei, C., & You, Z. (2024). Diabetes mellitus, systemic inflammation and overactive bladder. Frontiers in Endocrinology, 15, 1386639. https://doi.org/10.3389/fendo.2024.1386639

7. Huang, Y. C., & Chang, K. V. (2023). Kegel Exercises. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538272/

8. Kebapci, N., Yenilmez, A., Efe, B., Entok, E., & Demirustu, C. (2007). Bladder dysfunction in type 2 diabetic patients. Neurourology and Urodynamics, 26(6), 814–819. https://doi.org/10.1002/nau.20422

9. Lifford, K. L., Curhan, G. C., Hu, F. B., Barbieri, R. L., & Grodstein, F. (2005). Type 2 diabetes mellitus and risk of developing urinary incontinence. Journal of the American Geriatrics Society, 53(11), 1851–1857. https://doi.org/10.1111/j.1532-5415.2005.53565.x

10. Ngai, H. Y., Yuen, K. S., Ng, C. M., Cheng, C. H., & Chu, S. P. (2017). Metabolic syndrome and benign prostatic hyperplasia: An update. Asian Journal of Urology, 4(3), 164–173. https://doi.org/10.1016/j.ajur.2017.05.001

11. Panagiotakos, D. B., Tzima, N., Pitsavos, C., Chrysohoou, C., Papakonstantinou, E., Zampelas, A., & Stefanadis, C. (2005). The relationship between dietary habits, blood glucose and insulin levels among people without cardiovascular disease and type 2 diabetes; the ATTICA study. Review of Diabetic Studies, 2(4), 208–215. https://doi.org/10.1900/RDS.2005.2.208

12. Snowling, N. J., & Hopkins, W. G. (2006). Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis. Diabetes Care, 29(11), 2518–2527. https://doi.org/10.2337/dc06-1317

13. Trikkalinou, A., Papazafiropoulou, A. K., & Melidonis, A. (2017). Type 2 diabetes and quality of life. World Journal of Diabetes, 8(4), 120–129. https://doi.org/10.4239/wjd.v8.i4.120

14. Vasanth, R., Ganesh, A., & Shanker, R. (2017). Impact of stress on type 2 diabetes mellitus management. Psychiatria Danubina, 29(Suppl 3), 416–421. PMID: 28953801

15. Weinberg Sibony, R., Segev, O., Dor, S., & Raz, I. (2023). Drug therapies for diabetes. International Journal of Molecular Sciences, 24(24), 17147. https://doi.org/10.3390/ijms242417147

16. Xu, D., Gao, J., Wang, X., Huang, L., & Wang, K. (2017). Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China. Journal of Diabetes Complications, 31(8), 1254–1258. https://doi.org/10.1016/j.jdiacomp.2017.05.001

17. Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016). Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgraduate Medical Journal, 92(1084), 63–69. https://doi.org/10.1136/postgradmedj-2015-133281